Precision BioSciences Inc... (DTIL)
4.57
-0.52 (-10.22%)
At close: Mar 26, 2025, 3:16 PM
-10.22% (1D)
| Bid | 4.5 |
| Market Cap | 36.07M |
| Revenue (ttm) | 81.33M |
| Net Income (ttm) | 9.34M |
| EPS (ttm) | 0.4 |
| PE Ratio (ttm) | 11.43 |
| Forward PE | -0.58 |
| Analyst | Buy |
| Ask | 4.65 |
| Volume | 299,275 |
| Avg. Volume (20D) | 503,625 |
| Open | 5.07 |
| Previous Close | 5.09 |
| Day's Range | 4.30 - 5.07 |
| 52-Week Range | 3.61 - 15.97 |
| Beta | 1.59 |
About DTIL
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is i...
Industry Biotechnology
Sector Healthcare
IPO Date Mar 28, 2019
Employees 108
Stock Exchange NASDAQ
Ticker Symbol DTIL
Analyst Forecast
According to 3 analyst ratings, the average rating for DTIL stock is "Buy." The 12-month stock price forecast is $34, which is an increase of 643.98% from the latest price.
Stock ForecastsNext Earnings Release
Precision BioSciences Inc. is scheduled to release its earnings on Mar 26, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
Just now
Precision BioSciences shares are trading lower fol...
Unlock content with
Pro Subscription
1 month ago
+9.71%
Precision Biosciences shares are trading higher after the company announced initial results from the first administration of PBGene-HBV in Cohort 1 of the ELIMINATE-B trial.
